晨光生物科技集团股份有限公司 2021 年第一季度报告全文 晨光生物科技集团股份有限公司 2021 年第一季度报告 2021-065 2021 年 04 月 1 晨光生物科技集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证季度报告中财务报表的真实、准确、完整。 2 晨光生物科技集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------|------------------|---------------- ...

Financial Performance - The company reported a total revenue of 532,773,991 RMB for the year 2020, with a cash dividend distribution of 1 RMB per 10 shares to all shareholders[7]. - The company's operating revenue for 2020 was CNY 3,912,935,282.07, representing a 19.84% increase compared to CNY 3,265,232,815.43 in 2019[20]. - The net profit attributable to shareholders for 2020 was CNY 267,741,336.03, a 38.32% increase from CNY 193,572,517.02 in 2019[20]. - Basic earnings per share for 2020 were CNY 0.5540, up 46.99% from CNY 0.3769 in 2019[20]. - The total assets at the end of 2020 were CNY 4,654,478,102.66, reflecting a 3.27% increase from CNY 4,507,082,722.33 at the end of 2019[20]. - The net assets attributable to shareholders increased by 18.08% to CNY 2,064,141,483.17 from CNY 1,748,100,417.02 in 2019[20]. - The company reported a quarterly revenue of CNY 1,204,930,544.82 in Q4 2020, which was the highest among the four quarters[23]. - The diluted earnings per share for 2020 were CNY 0.5275, a 39.96% increase from CNY 0.3769 in 2019[20]. - The weighted average return on equity for 2020 was 14.36%, up from 10.65% in 2019[20]. - The company reported a non-operating income of approximately ¥42.24 million, a significant increase from ¥15.08 million in 2019, representing a growth of 179.5%[27]. - The company received government subsidies amounting to ¥53.76 million in 2020, compared to ¥19.49 million in 2019, indicating a growth of 175.5%[27]. Market Strategy and Development - The company aims to build a global natural extract industry base, emphasizing the importance of global resource allocation to achieve this goal[5]. - The company’s development strategy includes expanding its market presence and enhancing product offerings through new technologies and research[5]. - The company is committed to addressing challenges posed by international operations, including legal and cultural differences, to ensure sustainable growth[5]. - The company has established raw material bases in regions such as Xinjiang, Yunnan, and India, and is currently trialing raw material cultivation in Zambia[34]. - The company employs a market-oriented R&D model that includes stages from small trials to industrial production, ensuring alignment with market needs[34]. - The company has a complete procurement, R&D, production, and sales model, continuously improving its operational strategies based on market demands[34]. - The company is focusing on the rapid development of secondary products, including spice extracts and nutritional extracts, to improve profitability and operational resilience[166]. - The company intends to expand its OEM business in health food products and develop new products in the premium oil sector, aiming for significant growth in these areas[168]. Risk Management - The company plans to conduct thorough research before overseas investments to mitigate risks associated with foreign laws, taxes, and political stability[5]. - The company will actively use financial instruments to accelerate foreign exchange settlement and reduce the impact of exchange rate volatility on its operating performance[5]. - The company has not identified any new significant risks that could adversely affect its operations in the next reporting period[5]. - Foreign exchange fluctuations pose a risk as overseas revenue is a significant part of the company's income, primarily priced in USD; the company plans to use financial instruments to mitigate these risks[182]. - The company will conduct thorough research before overseas investments to minimize risks associated with international operations[181]. Research and Development - The company is committed to building a first-class research and development platform for natural extracts, attracting top talent to drive technological innovation[53]. - The company has established 21 technology platforms, including 5 national-level platforms, enhancing its research and development capabilities[56]. - The company has been awarded 65 technology-related awards at national, provincial, and municipal levels, including 2 National Science and Technology Progress Second Prizes[56]. - The company has completed 35 technology achievement appraisals, with 9 recognized as "internationally leading" and 12 as "internationally advanced"[57]. - The company has applied for 341 patents, with 216 granted, and published 143 papers out of 198 submissions[57]. - The company is committed to increasing R&D efforts to enhance product competitiveness in response to potential changes in export tax rebate policies[181]. Product Offerings and Market Position - The company’s product offerings include natural pigments, spices, nutritional extracts, and oils, catering to various industries such as food, pharmaceuticals, and cosmetics[31]. - Morning Glory Biotechnology has become the largest listed company in the domestic plant extract industry and ranks among the top tier globally, gradually catching up with or surpassing foreign leaders like Frutarom and Kalsec[37]. - The company has three main products—capsanthin, capsaicin, and lutein—ranking first or among the top in the world, with other products like pepper extract and curcumin in a rapid growth phase[37]. - The company’s main products, including chili red, lutein, and lycopene, rank among the top in the world, with stable growth in market share and profitability[86]. - The company aims to develop around ten world-leading products in the natural extraction industry, leveraging its 20 years of experience and strong brand reputation[86]. Financial Management and Shareholder Relations - The company’s profit distribution plan was approved, with no new shares being issued from capital reserves[7]. - The total cash dividend distributed for 2020 was 53.28 million yuan, representing 19.90% of the consolidated net profit attributable to shareholders[197]. - The cash dividend per 10 shares was set at 1.0 yuan (including tax), with a total of 532,773,991 shares as the base for distribution[190]. - The company plans to maintain a minimum cash dividend of 10% of the distributable profit annually, barring significant investment plans or cash expenditures[188]. - The company has consistently increased its cash dividend over the past three years, with 2020 showing a significant increase compared to previous years[195]. - The company has established a commitment to notify and facilitate any business opportunities that may compete with its operations[199]. - The company has implemented a share incentive plan to align the interests of shareholders and management[200]. Operational Efficiency - The company saved nearly 20,000 working hours through standardized and IT-driven management processes, significantly improving work efficiency and accuracy[80]. - The company has completed several projects aimed at improving production efficiency and reducing costs, including the installation of a new biomass steam boiler[124]. - The company has successfully implemented safety enhancement modifications in the production workshop[121]. - The company has completed the automatic palletizing robot transformation in the filling workshop, improving automation levels[121]. - The company aims to improve its production efficiency and cost advantages through integrated production and resource utilization strategies[164]. Environmental and Social Responsibility - The company is committed to enhancing its environmental protection measures and has invested in strict environmental monitoring systems to comply with increasing regulatory standards[180]. - The company donated over 10 million yuan worth of medical supplies during the pandemic, including alcohol, masks, protective clothing, and lycopene soft capsules, contributing to the fight against COVID-19[81].

晨光生物科技集团股份有限公司 2020 年第三季度报告全文 晨光生物科技集团股份有限公司 2020 年第三季度报告 2020-146 2020 年 10 月 1 晨光生物科技集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证季度报告中财务报表的真实、准确、完整。 2 晨光生物科技集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------|-----------------------------------------------------|-------|----- ...

晨光生物科技集团股份有限公司 2020 年半年度报告全文 晨光生物科技集团股份有限公司 2020 年半年度报告 2020-108 2020 年 08 月 1 晨光生物科技集团股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，投 资者及相关人士应当对此保持足够的风险认识，并且应当理解计划、预测与承 诺之间的差异。 公司在本报告第四节"经营情况讨论与分析"中"九、公司面临的风险和应对 措施"中详细描述了公司可能面临的风险及应对措施，敬请投资者特别关注相关 内容，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 晨光生物科技集团股份有限公司 2020 年半年度报告全文 目 录 | ...

晨光生物科技集团股份有限公司 2020 年第一季度报告全文 晨光生物科技集团股份有限公司 2020 年第一季度报告 2020-055 2020 年 04 月 1 晨光生物科技集团股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证季度报告中财务报表的真实、准确、完整。 2 晨光生物科技集团股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | ...

Financial Performance - The total revenue for 2019 was CNY 3,265,232,815.43, representing a 6.59% increase from CNY 3,063,440,575.35 in 2018[17]. - The net profit attributable to shareholders for 2019 was CNY 193,572,517.02, a 33.24% increase compared to CNY 145,283,057.15 in 2018[17]. - The net profit after deducting non-recurring gains and losses was CNY 178,488,174.16, up 47.25% from CNY 121,216,504.02 in 2018[17]. - The basic earnings per share for 2019 was CNY 0.3769, an increase of 33.04% from CNY 0.2833 in 2018[17]. - The total assets at the end of 2019 were CNY 4,507,082,722.33, a 34.25% increase from CNY 3,357,108,727.95 at the end of 2018[17]. - The net assets attributable to shareholders at the end of 2019 were CNY 1,748,100,417.02, a slight increase of 0.23% from CNY 1,744,120,502.21 at the end of 2018[17]. - The net cash flow from operating activities for 2019 was CNY -24,346,095.32, an improvement of 56.67% from CNY -56,182,968.88 in 2018[17]. - The weighted average return on equity for 2019 was 10.65%, up from 8.63% in 2018[17]. - The company reported a quarterly revenue of CNY 959,104,617.63 in Q4 2019, which was the highest among the four quarters[19]. Dividend Distribution - The profit distribution plan approved by the board proposes a cash dividend of 0.5 RMB per 10 shares, based on a total of 481,561,019 shares[4]. - The company distributed a cash dividend of 0.5 yuan per 10 shares, totaling 24,078,050.95 yuan for the year 2019[147]. - The total cash dividend, including other methods, amounted to 171,545,884.66 yuan, representing 100% of the total distributable profit[148]. - The cash dividend for 2019 accounted for 12.44% of the consolidated net profit attributable to shareholders[151]. - Over the past three years, the company has maintained a cash dividend distribution policy, with a minimum of 10% of the distributable profit allocated for cash dividends annually[145]. International Operations and Risks - The company aims to build a global natural extract industry base, with significant reliance on overseas revenue, which constitutes a large portion of total revenue[4]. - The company acknowledges potential risks from varying legal, tax, and foreign exchange regulations in different countries, which could adversely affect performance[4]. - The company’s overseas income is primarily settled in USD, making it sensitive to currency fluctuations[4]. - Future export volumes are expected to grow as production scales up, but may be impacted by changes in foreign exchange policies[4]. - The company emphasizes the importance of thorough research before project investments to minimize risks associated with overseas operations[4]. - The company is exposed to exchange rate fluctuations due to a significant portion of its revenue being generated from overseas sales, primarily settled in USD[140]. - The company benefits from export tax rebate policies, which enhance its competitiveness in international markets, but any changes in these policies could impact operational costs[141]. Research and Development - The company is focused on R&D with a market-oriented approach, implementing a phased development model for new products[29]. - The company has established 21 technology platforms, including 5 national-level platforms and 12 provincial-level platforms, contributing to a total of 60 technology-related awards received[38]. - The company has applied for 324 patents, with 206 patents granted, and has published 128 papers, showcasing its strong focus on research and development[40]. - The company has developed new products such as green coffee bean extract and pepper oil resin, enhancing its product portfolio to meet market demands[37]. - The company invested CNY 184,718,776.76 in R&D in 2019, representing 5.66% of its operating revenue[84]. - The number of R&D personnel increased to 117 in 2019, accounting for 8.74% of the total workforce[84]. Production and Supply Chain - The company is expanding its raw material bases in regions like Xinjiang, India, and Yunnan, and is trial planting in Zambia[29]. - The company has established a stable supply chain by collaborating with local farmers and agricultural institutions in regions like Xinjiang and Yunnan, ensuring a steady supply of high-quality raw materials[46]. - The company has developed a unique "three-in-one" planting model in collaboration with seed companies to ensure stable raw material supply[46]. - The company has successfully commercialized high-purity, application-oriented products, breaking foreign monopolies in the high-end application market[37]. - The company has implemented a cost control system that significantly reduces raw material procurement costs and improves production efficiency[47]. Market Position and Sales - The company’s major products include natural pigments and extracts, with key products like chili red pigment and lutein leading the industry[27]. - In 2019, the company achieved a sales volume of 5,896 tons of chili red pigment, maintaining its position as the world's number one for twelve consecutive years[52]. - The sales volume of feed-grade lutein reached 385 million grams, representing a year-on-year growth of approximately 18%[52]. - The sales volume of food-grade lutein increased by about 62% to 43.67 million grams[53]. - The company expanded its planting of marigold in Xinjiang to over 150,000 acres and in Yunnan to nearly 40,000 acres, contributing to local farmers' income and government support[53]. Financial Management and Investments - The company has not identified any new significant risks that could adversely affect operations in the next reporting period[4]. - The company has established a management system for raised funds to protect investor rights and ensure proper usage[105]. - The company has committed to not engage in any business that directly or indirectly competes with its main operations, ensuring no similar products are produced[152]. - The company has a clear and transparent profit distribution policy, ensuring that minority shareholders have the opportunity to express their opinions[146]. - The company has not faced any major litigation or arbitration matters during the reporting period[165]. Environmental and Social Responsibility - The company is actively investing in environmental protection facilities and has implemented a strict environmental monitoring system to comply with increasing regulatory standards[140]. - The company has implemented a clean production system with wastewater and waste gas recycling, achieving compliance with environmental standards[190]. - The company donated approximately CNY 100,000 to local education and public welfare initiatives during the reporting period[188]. Corporate Governance - The board of directors has confirmed the accuracy and completeness of the annual report, ensuring no misleading statements or omissions[3]. - The company has established a safety management department and emphasizes regular maintenance of production equipment to ensure safety[187]. - The company has maintained a continuous relationship with its auditing firm for 7 years, with an audit fee of RMB 826,000[164].

晨光生物科技集团股份有限公司 2019 年第三季度报告全文 晨光生物科技集团股份有限公司 2019 年第三季度报告 2019-171 2019 年 10 月 1 晨光生物科技集团股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证季度报告中财务报表的真实、准确、完整。 2 晨光生物科技集团股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------------|----------------- ...

Financial Performance - The company reported a significant increase in revenue, with total operating income reaching RMB 1.5 billion, representing a year-on-year growth of 25%[5]. - Total revenue for the reporting period reached ¥1,610,469,899.53, an increase of 24.27% compared to ¥1,295,956,241.87 in the same period last year[23]. - Net profit attributable to shareholders was ¥111,025,496.29, up 17.38% from ¥94,588,768.77 year-on-year[23]. - Basic earnings per share increased by 22.22% to ¥0.22, compared to ¥0.18 in the same period last year[23]. - The company's operating revenue for the reporting period reached RMB 1,610,469,899.53, representing a year-on-year increase of 24.27% compared to RMB 1,295,956,241.87 in the same period last year[69]. - The gross profit margin for the natural colorants/spices/nutrition and medicinal products segment increased, with revenue of RMB 825,206,000 and a gross profit of RMB 180,970,100, reflecting year-on-year growth of 37% and 27% respectively[71]. - The net profit for the first half of 2019 was CNY 108,847,705.09, representing a 16.7% increase from CNY 93,304,480.91 in the first half of 2018[188]. - The total comprehensive income for the first half of 2019 was CNY 111,386,001.00, compared to CNY 86,898,275.10 in the same period of 2018, reflecting a growth of 28.0%[189]. Cash Flow and Financial Position - Net cash flow from operating activities surged by 159.16% to ¥429,174,323.95, compared to ¥165,600,957.26 in the previous year[23]. - Cash and cash equivalents increased by 61.78%, mainly due to the accumulation of unused funds from guarantees and temporary receivables[36]. - The company's total liabilities decreased to RMB 1,515,847,690.53 from RMB 1,616,920,521.54, indicating a reduction in financial obligations[179][180]. - The company's equity attributable to shareholders rose to RMB 1,810,075,763.73 from RMB 1,744,120,502.21, reflecting retained earnings growth[180]. - The cash flow from financing activities showed a net outflow of CNY 249,536,789.45, compared to CNY 20,795,908.50 in the first half of 2018[196]. Investments and R&D - The company plans to continue increasing investments in natural colorants/spices/nutrition and medicinal products in the second half of the year to enhance operational performance in this segment[72]. - The company's R&D expenses amounted to RMB 68,232,441.46, a slight decrease of 2.53% from RMB 70,005,984.59 in the previous year, while R&D project costs increased significantly by 107.80% to RMB 26,095,760.42[70]. - The company has 20 technology platforms, including 5 national-level platforms, enhancing its R&D capabilities and industry technology support[40]. - The company has applied for 298 patents, with 181 patents granted, indicating a strong focus on innovation[43]. - The company has established a research center with advanced laboratories and is collaborating with universities to develop industry-leading products, including key technologies for natural extract crystallization[58]. Market and Product Development - The company remains a leader in the natural plant extract sector, with key products like chili red pigment and lutein ranking first in the industry[31]. - The company has seen rapid growth in products such as cottonseed dephenolized protein and other natural extracts, indicating a strong market expansion[31]. - The company achieved a sales volume of over 3,000 tons of its main product, chili red, representing a year-on-year growth of 31%[54]. - The sales volume of ordinary lutein increased by 35% year-on-year, further expanding market share[54]. - The company has developed and launched 6 types of SC health products, with 10 more in development and 6 registered health food products[54]. Risk Management and Compliance - The company is actively utilizing financial instruments such as export financing and forward foreign exchange contracts to mitigate currency fluctuation risks[5]. - Future growth strategies include thorough market research before project investments to minimize risks associated with overseas operations[5]. - The management has indicated that there are no significant risks that could adversely affect the company's operations in the next reporting period[5]. - The company is committed to maintaining compliance with international standards and certifications to enhance product safety and quality[11]. - The company has established a management system for raised funds to protect investor rights and ensure compliance with regulations[87]. Shareholder and Governance - No cash dividends or stock bonuses will be distributed to shareholders for this reporting period[6]. - The annual shareholders meeting had a participation rate of 35.93%, representing 183,910,738 shares, which is 35.93% of the total voting shares[115]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[116]. - The company reported a commitment compliance rate of 100% among its shareholders, with no violations found during the reporting period[119]. - The company has not reported any significant changes in the status of its pledged assets or raised funds management[88]. Social Responsibility and Environmental Impact - The company has increased investments in environmental protection facilities to comply with stricter regulations and reduce production impacts[110]. - The company has actively fulfilled its social responsibilities, including safety management and employee training programs[145]. - The company has expanded its marigold planting area to 130,000 mu, benefiting 29,000 impoverished households[145]. - The company has implemented low nitrogen combustion technology in its natural gas boilers, achieving ultra-low emissions standards[142].

Group 1: Company Overview - Morning Light Biological Technology Group Co., Ltd. is participating in the 2019 Annual Investor Online Reception Day on May 15, 2019 [1] - The company aims to provide comprehensive insights into its situation, development strategy, operational status, and sustainable development [1] Group 2: Event Details - The event will take place from 15:00 to 17:00 on May 15, 2019, organized by the Hebei Regulatory Bureau of the China Securities Regulatory Commission [1] - Investors can participate through the online platform "Panorama Roadshow" [1] Group 3: Engagement and Interaction - Company executives will engage in interactive communication with investors during the event [1] - The company encourages active participation from investors [1]

晨光生物科技集团股份有限公司 2019 年第一季度报告全文 晨光生物科技集团股份有限公司 2019 年第一季度报告 2019-066 2019 年 04 月 1 晨光生物科技集团股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢庆国、主管会计工作负责人周静及会计机构负责人(会计主管 人员)宋书军声明：保证季度报告中财务报表的真实、准确、完整。 2 晨光生物科技集团股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|---------|-----------------------------------------------------|------ ...